Adaptimmune(ADAP) Newsfile·2024-10-31 21:20Core Viewpoint - Adaptimmune Therapeutics plc is set to report its Q3 2024 financial results and business updates on November 13, 2024, after US market close, indicating ongoing developments in its cell therapy for solid tumor cancers [2]. Company Overview - Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies aimed at transforming cancer treatment [4]. - The company utilizes a unique engineered T-cell receptor (TCR) platform to create T-cells that target and destroy various solid tumor types [4]. Upcoming Events - A live webcast will follow the financial results announcement at 4:30 p.m. EDT (9:30 p.m. GMT) on the same day [2]. - Call-in information for the webcast is provided for both US/Canada and international participants, encouraging early dial-in [3]. Additional Information - The press release will be accessible in the investor section of Adaptimmune's corporate website, ensuring transparency and availability of information for stakeholders [3].